Reporte de caso
Clozapine-Induced Eosinophilia: a Case Report
Eosinofilia Inducida por Clozapina: un Caso Clínico
Read
145
Timeswas read the article
64
Total PDF
81
Total HTML
Share statistics
array:23 [ "pii" => "S2530312023000358" "issn" => "25303120" "doi" => "10.1016/j.rcpeng.2021.04.008" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "447" "copyright" => "Asociación Colombiana de Psiquiatría" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Rev Colomb Psiquiatr. 2023;52:161-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S2530312023000267" "issn" => "25303120" "doi" => "10.1016/j.rcpeng.2021.04.005" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "454" "copyright" => "Asociación Colombiana de Psiquiatría" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Rev Colomb Psiquiatr. 2023;52:165-70" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case Report</span>" "titulo" => "Hepatoxicity induced by clozapine: Case report and brief review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "165" "paginaFinal" => "170" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hepatotoxicidad inducida por clozapina: reporte de caso y revisión breve de la literatura" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joshep Revilla-Zúñiga, Joise Cornejo-Del Carpio, Lizardo Cruzado" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Joshep" "apellidos" => "Revilla-Zúñiga" ] 1 => array:2 [ "nombre" => "Joise" "apellidos" => "Cornejo-Del Carpio" ] 2 => array:2 [ "nombre" => "Lizardo" "apellidos" => "Cruzado" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0034745021000871" "doi" => "10.1016/j.rcp.2021.04.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0034745021000871?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530312023000267?idApp=UINPBA00004N" "url" => "/25303120/0000005200000002/v1_202307261121/S2530312023000267/v1_202307261121/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2530312023000255" "issn" => "25303120" "doi" => "10.1016/j.rcpeng.2021.04.004" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "445" "copyright" => "Asociación Colombiana de Psiquiatría" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Rev Colomb Psiquiatr. 2023;52:156-60" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case Report</span>" "titulo" => "Burns in the context of a shared psychotic disorder in a Colombian referral centre: A case report" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "156" "paginaFinal" => "160" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Quemaduras en el contexto de un trastorno psicótico compartido en un centro de referencia colombiano: reporte de caso" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1068 "Ancho" => 905 "Tamanyo" => 128143 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Patient A. Pattern of iron burns.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Diego Fernando Alarcón Ariza, Laura Cristina Zambrano Jerez, Carlos Enrique Ramírez Rivero, Jorge Andrés Niño García, Adriana Catalina Ruiz Quecan, Gonzalo Andrés Domínguez Alvarado" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Diego Fernando" "apellidos" => "Alarcón Ariza" ] 1 => array:2 [ "nombre" => "Laura Cristina" "apellidos" => "Zambrano Jerez" ] 2 => array:2 [ "nombre" => "Carlos Enrique" "apellidos" => "Ramírez Rivero" ] 3 => array:2 [ "nombre" => "Jorge Andrés" "apellidos" => "Niño García" ] 4 => array:2 [ "nombre" => "Adriana Catalina" "apellidos" => "Ruiz Quecan" ] 5 => array:2 [ "nombre" => "Gonzalo Andrés" "apellidos" => "Domínguez Alvarado" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530312023000255?idApp=UINPBA00004N" "url" => "/25303120/0000005200000002/v1_202307261121/S2530312023000255/v1_202307261121/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Reporte de caso</span>" "titulo" => "Clozapine-Induced Eosinophilia: a Case Report" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "161" "paginaFinal" => "164" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Francesco Monteleone, Márcia Gonçalves, Luís Fonseca, Sónia Simões, Andreia Gonçalves, Eduarda Machado, João Fonseca" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Francesco" "apellidos" => "Monteleone" "email" => array:1 [ 0 => "francescomonteleone@hospitaldeguimaraes.min-saude.pt" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Márcia" "apellidos" => "Gonçalves" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Luís" "apellidos" => "Fonseca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Sónia" "apellidos" => "Simões" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Andreia" "apellidos" => "Gonçalves" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Eduarda" "apellidos" => "Machado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "João" "apellidos" => "Fonseca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Psychiatry and Mental Health Department of Hospital Senhora da Oliveira, Guimarães, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "USF D’as Terras de Lanhoso, Povoa de Lanhos, Braga, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eosinofilia Inducida por Clozapina: un Caso Clínico" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Clozapine is an atypical antipsychotic eligible for treatment-resistant schizophrenia.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">1</span></a> It is frequently the best and the only pharmacologic choice in resistant schizophrenia. However, its use is feared by many professionals due to its possible adverse effects, like eosinophilia.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Case report</span><p id="par0010" class="elsevierStylePara elsevierViewall">A schizophrenic white 26-years-old man was seen in acute setting for behavioural changes. He presented a poor and disorganized speech, mystical, persecutory, and messianic delusions, auditory hallucinations, soliloquies, and unmotivated laughter. Due to these symptoms and his lack of insight, he was compulsively hospitalized. He had history of oppositional disorder diagnosed in adolescence, poor therapeutic adhesion, mild cognitive impairment, allergic rhinitis, egg allergy and cannabinoids abuse since the age of 20.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The diagnostic workup including EKG, a thorough blood and urine test, brain CAT scan showed no abnormalities.</p><p id="par0020" class="elsevierStylePara elsevierViewall">After several weeks, his symptoms did not improve despite several trials with a combination of antipsychotics. A diagnosis of treatment-resistant schizophrenia was considered, and clozapine titration was started with close haematology monitoring. A progressive and significant psychopathological improvement was observed.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Thirteen days after clozapine was initiated, eosinophil count increased to 600/cmm. Titration of clozapine was suspended, and its dose was kept stable. Patient was physically asymptomatic and presented no other analytical changes. However, eosinophil count kept increasing, peaking 7900/cmm (53% of total leucocyte count) on the sixteenth day of treatment. Clozapine and all medications that could also induce eosinophilia, according to the available literature, were suspended. The eosinophil count remained increasing in the next five days before gradually returning to the reference values one week later.</p><p id="par0030" class="elsevierStylePara elsevierViewall">A clinical exhaustive evaluation by Internal Medicine revealed no cause for eosinophilia.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Therefore, a diagnostic of a clozapine-induced eosinophilia was made.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Patient was discharged home two and half months after admission medicated with lorazepam 7.5<span class="elsevierStyleHsp" style=""></span>mg per day and haloperidol 5<span class="elsevierStyleHsp" style=""></span>mg per day. His behaviour was stable but residual delusional symptoms persisted.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Discussion</span><p id="par0045" class="elsevierStylePara elsevierViewall">Clozapine is a second generation antipsychotic eligible for treatment-resistant schizophrenia, suicide risk in patients with schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, comorbid substance abuse, psychosis in Parkinson's disease, and prevention and treatment of tardive dyskinesia.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">1</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">It is frequently the best, and unfortunately the only, choice in resistant schizophrenia, being considered in this context superior to other antipsychotics.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">2</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Initially developed in the early 1970's but its use rapidly decreased after reported cases of treatment-induced, fatal, agranulocytosis,<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">3</span></a> perhaps the most feared side effect of clozapine in the world. Despite this, it is not the most common adverse effect, affecting just 0.8% of patients receiving their therapy.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">3</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">The use of clozapine is associated with numerous adverse effects, involving up to 76% of patients treated and which motivates stopping treatment in 17% of cases.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">1</span></a> The most common adverse effects include agranulocytosis, convulsions, sialorrhea, orthostasis, tachycardia, constipation, and somnolence.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">1</span></a> Pancreatitis, hepatitis, colitis, nephritis, and myocarditis have also been described.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">4</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Eosinophilia is a relatively common, non-dose-dependent adverse effect of clozapine treatment, usually during the first year, mainly the first four weeks.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">1,3,5</span></a> The reported incidence varies significantly, ranging from 1 to 13%.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">1,5,6</span></a> The largest study, with 2404 patients, in Italy, found the incidence of 2.2%.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">7</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">Clozapine-induced eosinophilia seems to be linked, according to various authors, to allergic immunological phenomena including type <span class="elsevierStyleSmallCaps">I</span> hypersensitivity reaction and stimulation of T lymphocytes, however the etiopathogenesis is still unknown.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">1,2,4,5,8</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">In agreement with several authors, most cases of eosinophilia during clozapine treatment are transient<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">9</span></a> and, in recent literature, have been defined as “benign” eosinophilia in contrast to cases of eosinophilia linked to systemic inflammation and organ damage.</p><p id="par0080" class="elsevierStylePara elsevierViewall">However, in some cases, the onset of eosinophilia may predict subsequent neutropenia, myocarditis, eosinophilic colitis, pancreatitis and toxic hepatitis,<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">1,5</span></a> therefore the association with possible more serious inflammatory processes makes it more difficult to weigh the right conduct in spite of this clinical situation.</p><p id="par0085" class="elsevierStylePara elsevierViewall">Despite this, most cases of eosinophilia during clozapine treatment are transient and self-limiting<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">9</span></a> and, in recent literature, have been defined as “benign” eosinophilia in contrast to cases of eosinophilia linked to systemic inflammation and organ damage. In “benign eosinophilia”, occurs in asymptomatic patients with no systemic inflammation, it is widely believed that the withdrawal of the drug is not necessary and that close monitoring of the patient is enough.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">1,8</span></a>. Many of these cases can resolve spontaneously without stopping treatment<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">4,8,10</span></a>; indeed, many successful cases have also been described both in continuing treatment in patients who develop eosinophilia, and in restarting treatment in patients with a history of clozapine-induced eosinophilia.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">2-4,6,8,11,12</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Conclusions</span><p id="par0090" class="elsevierStylePara elsevierViewall">Currently, there are no specific guidelines on the management of hematological side effects like eosinophilia. The only indications available now are those of the manufacturer, which suggests stopping the treatment when the eosinophil count is higher than 3<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span> and possibly restart when it is below 1<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>. Several experts have suggested in recent years that the risk of discontinuing therapy, when all other medical conditions have been ruled out, outweighs any benefits.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">13</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">In the patient under examination, during the hospitalization, we decided to follow the manufacturer's instructions, therefore, withdraw the clozapine. At the time of discharge, there was doubt about the possibility of the patient try to hide part of his productive symptoms. He was in a long-term hospitalization, tired, and already without criteria for compulsive hospitalization than he was discharged and oriented for internal medicine and psychiatry ambulatory follow-up.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Recently, he was discharged from the internal medicine consultation definitively ruled out any other medical condition possibly causing the reported clinical case. Regarding psychiatric follow-up, cognitive decline, and loss of functionality as well as the prevalence of negative symptoms remains evident in this patient. Actually, he is relatively under-medicated compared to the case initially presented, which may be due, in our opinion, mainly to a defensive posture towards the interviewer, in order to avoid new admissions, which in our experience is not uncommon.</p><p id="par0105" class="elsevierStylePara elsevierViewall">For this reason, it maintains a tight ambulatory control without ruling out the possibility of a new rechallenge with clozapine or referral for electroconvulsive therapy.</p><p id="par0110" class="elsevierStylePara elsevierViewall">Faced with the recent literature, we agree with the many authors who recommend the continuation of clozapine therapy when eosinophilia exists in the absence of symptoms and no evidence of systemic inflammation and organ damage.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Today, treatment-resistant schizophrenia accounts for about one third of patients with schizophrenia<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">11</span></a> and, faced with the lack of therapeutic responses,<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">2</span></a> it is necessary to make the best use of the available resources. In the case of clozapine, therefore, the correct description and definition of adequate management of any adverse effects is essential. As many authors have pointed out, this would prevent our patients from unnecessary loss of therapeutic opportunities<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">3</span></a> and, consequently, of their quality of life.</p><p id="par0120" class="elsevierStylePara elsevierViewall">We reinforce the idea that the decision to stop clozapine treatment must be made based on patient's clinical and analytical evolution<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">12</span></a> considering the highly unfavorable cost-benefit ratio that <span class="elsevierStyleItalic">a priori</span> withdrawal of medication has.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:9 [ 0 => array:3 [ "identificador" => "xres1939293" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Case report" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Discussion" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1671063" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1939294" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Reporte de caso" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Discusión" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1671064" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Case report" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Discussion" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Conclusions" ] 8 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2021-03-27" "fechaAceptado" => "2021-04-21" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1671063" "palabras" => array:4 [ 0 => "Clozapine-induced eosinophilia" 1 => "Eosinophilia" 2 => "Clozapine" 3 => "Schizophrenia" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1671064" "palabras" => array:4 [ 0 => "Eosinofilia inducida por clozapina" 1 => "Eosinofilia" 2 => "Clozapina" 3 => "Esquizofrenia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clozapine is an atypical antipsychotic drug eligible for treatment-resistant schizophrenia. It frequently represents the best and the only choice in resistant schizophrenia. However, its use is feared by many professionals due to its possible adverse effects, such as eosinophilia.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Case report</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">We report a case of a young white male suffering from treatment-resistant schizophrenia who rapidly developed eosinophilia after starting clozapine.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Discussion</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">We present a case of a 26-year-old white man diagnosed with schizophrenia with poor clinical response to several antipsychotics owing to which clozapine was started. Psychotic symptoms improved dramatically but a progressively ascendant eosinophilia was reported during serial haematological analyses. The patient remained physically asymptomatic. An exhaustive assessment with ancillary diagnostic tests revealed no cause for eosinophilia. Thus, a diagnosis of clozapine-induced eosinophilia was made. The drug was discontinued and eosinophil count progressively returned to normal but psychotic symptoms worsened.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Clozapine treatment is frequently feared due to its possible side effects and complications, delaying its use in refractory schizophrenia. Also, to our knowledge, there are no specific guidelines on how to manage haematological side effects such as eosinophilia. This is problematic as, in some cases, it may lead to an unnecessary withdrawal of clozapine with a worsening of psychotic symptoms. We present a brief discussion of the recent literature on the subject.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Case report" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Discussion" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducción</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">La clozapina es un fármaco antipsicótico atípico eligible para la esquizofrenia resistente al tratamiento. Con frecuencia representa la mejor y la única opción para la esquizofrenia resistente. Sin embargo, muchos profesionales temen utilizarla por sus posibles efectos adversos, como la eosinofilia.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Reporte de caso</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se expone el caso de un joven blanco que sufre esquizofrenia resistente al tratamiento y desarrolló eosinofilia rápidamente tras comenzar el tratamiento con clozapina.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Discusión</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Varón de 26 años con diagnóstico de esquizofrenia y mala respuesta clínica a varios antipsicóticos, por lo que se inició clozapina. Los síntomas psicóticos mejoraron drásticamente, pero los análisis hematológicos seriados informaron una eosinofilia en ascenso progresivo. El paciente permaneció físicamente asintomático. Una evaluación exhaustiva con pruebas de diagnóstico complementarias no reveló ninguna causa de eosinofilia. Por lo tanto, se diagnosticó eosinofilia inducida por clozapina. Se suspendió el fármaco, el recuento de eosinófilos volvió progresivamente a la normalidad, pero los síntomas psicóticos empeoraron.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">A menudo se teme tratar con clozapina por sus posibles efectos secundarios y sus complicaciones, lo cual retrasa su uso en la esquizofrenia refractaria. Además, hasta donde sabemos, no existen pautas específicas sobre cómo tratar los efectos secundarios hematológicos como la eosinofilia. Esto es problemático porque, en algunos casos, puede conducir a suspender innecesariamente la clozapina y que empeoren los síntomas psicóticos. Se presenta una breve discusión de la literatura reciente sobre el tema.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Reporte de caso" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Discusión" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:13 [ 0 => array:3 [ "identificador" => "bib0070" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eosinofilia y serositis inducida por clozapinaClozapine-induced eosinophilia and serositis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Demelo-Rodríguez" 1 => "J.M. Miguel-Yanes" 2 => "S. Gómez-Vallejo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Psiquiatr Salud Ment." "fecha" => "2019" "volumen" => "12" "paginaInicial" => "120" "paginaFinal" => "131" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0075" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine-associated severe eosinophilia following lithium rebound neutropenia: A case report" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kikuchi" 1 => "N. Yasui-Furukori" 2 => "S. Yokoyama" 3 => "C. Hasegawa" 4 => "A. Kokubun" 5 => "S. Katsukura" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Neuropsychopharmacol Rep." "fecha" => "2020;40(4):388-91." ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0080" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful rechallenge with clozapine after treatment associated eosinophilia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P. McArdle" 1 => "D.J. Siskind" 2 => "U. Kolur" 3 => "S. Parker" 4 => "N. Korman" 5 => "S. Purushothaman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1039856216654399" "Revista" => array:6 [ "tituloSerie" => "Australas Psychiatry." "fecha" => "2016" "volumen" => "24" "paginaInicial" => "365" "paginaFinal" => "367" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27324147" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0085" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuation with clozapine after eosinophilia: a case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y.-C. Ho" 1 => "H.-L. Lin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Ann Gen Psychiatry." "fecha" => "2017" "paginaInicial" => "16" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0090" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine induced eosinophilia: An often neglected important adverse effect" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.K. Kadiyala" 1 => "M.A. Ahmed" 2 => "D.A. Pinto" 3 => "J.P. Mathai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/0019-5545.171849" "Revista" => array:6 [ "tituloSerie" => "Indian J Psychiatry." "fecha" => "2015" "volumen" => "57" "paginaInicial" => "429" "paginaFinal" => "430" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26816437" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0095" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Allergic to clozapine: a case of clozapine-associated eosinophilia with pleural effusions followed by pancreatitis on clozapine rechallenge" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.V. Burns" 1 => "L.E. Halpin" 2 => "S.L.S. Rosseel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/JCP.0000000000001187" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychopharmacol." "fecha" => "2020" "volumen" => "40" "paginaInicial" => "199" "paginaFinal" => "200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32134858" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0100" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blood dyscrasias in clozapine-treated patients in Italy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.L. Deliliers" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Haematologica." "fecha" => "2000" "volumen" => "85" "paginaInicial" => "233" "paginaFinal" => "237" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10702809" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0105" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.de. Filippis" 1 => "P. Soldevila-Matías" 2 => "P. Fazio" 3 => "D. De Guinart" 4 => "I. Fuentes-Durá" 5 => "J.M. Rubio" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/17512433.2020.1787831" "Revista" => array:7 [ "tituloSerie" => "Expert Rev Clin Pharmacol." "fecha" => "2020" "volumen" => "13" "paginaInicial" => "875" "paginaFinal" => "883" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32576056" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1470204517304217" "estado" => "S300" "issn" => "14702045" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0110" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Simple pulmonary eosinophilia associated with clozapine treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Hashimoto" 1 => "T. Maeda" 2 => "R. Okubo" 3 => "H. Narita" 4 => "I. Kusumi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/JCP.0000000000000256" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychopharmacol." "fecha" => "2015" "volumen" => "35" "paginaInicial" => "99" "paginaFinal" => "101" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25514065" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0115" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eosinophilia and parotitis occurring early in clozapine treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "B.N. Saguem" 1 => "S. Bouhlel" 2 => "C. Salem" 3 => "Ben" 4 => "B.B.H. Ali" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11096-015-0163-7" "Revista" => array:6 [ "tituloSerie" => "Int J Clin Pharm." "fecha" => "2015" "volumen" => "37" "paginaInicial" => "992" "paginaFinal" => "995" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26373547" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0120" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rechallenge following clozapine-associated eosinophilia: a case report and literature review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Lally" 1 => "N. ÓConnor" 2 => "S. Fullam" 3 => "N. Corcoran" 4 => "A. OʼReilly" 5 => "J. Jordan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/JCP.0000000000001079" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychopharmacol." "fecha" => "2019" "volumen" => "39" "paginaInicial" => "504" "paginaFinal" => "506" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31335444" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0125" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine-induced eosinophilia, elevated C-reactive protein and fever" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.M. Torres" 1 => "N. García-Sánchez" 2 => "M. Barberá" 3 => "J.J. Plumed-Domingo" 4 => "P.M. Moral" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Esp Psiquiatr." "fecha" => "2019" "volumen" => "47" "paginaInicial" => "121" "paginaFinal" => "126" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31233211" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0130" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Nielsen" 1 => "C.U. Correll" 2 => "P. Manu" 3 => "J.M. Kane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4088/JCP.12r08064" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry." "fecha" => "2013" "volumen" => "74" "paginaInicial" => "603" "paginaFinal" => "613" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23842012" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25303120/0000005200000002/v1_202307261121/S2530312023000358/v1_202307261121/en/main.assets" "Apartado" => array:4 [ "identificador" => "66620" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case report" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25303120/0000005200000002/v1_202307261121/S2530312023000358/v1_202307261121/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530312023000358?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 0 | 1 |
| 2024 October | 6 | 9 | 15 |
| 2024 September | 10 | 12 | 22 |
| 2024 August | 11 | 17 | 28 |
| 2024 July | 13 | 7 | 20 |
| 2024 June | 13 | 0 | 13 |
| 2024 May | 10 | 4 | 14 |
| 2024 April | 17 | 15 | 32 |
